This study aims to understand the effectiveness and safety of Motilium among study participants with dyspepsia-related symptoms in real-world settings in China.

Inclusion Criteria:

• Individuals purchased OTC Motilium at pharmacies for themselves for the treatment of one or more dyspepsia-related symptoms including postprandial fullness, early satiation, epigastric pain, epigastric burning, belching, epigastric bloating, nausea, and vomiting
• Provided signed and dated informed consent

Exclusion Criteria:

• Individuals who suffered from dyspepsia-related symptoms ≥ 3 days/week for at least 3 months prior to joining the study
• Individuals who suffered exclusively from heartburn
• Individuals taking or planning to take dyspepsia-related medication, including but not limited to proton pump inhibitors, hydrotalcite, Talcid, Sanjiu Weitai, JianWeiXiaoShiPian, Jiangzhong Jianwei, Digestive enzyme, Itopride, Mosapride, and Famotidine
• History of, or current, cardiac disease or cardiac arrhythmias including QT prolongation, ventricular tachycardia, ventricular fibrillation and Torsades de Pointes
• Any of the following warning signs: black stool, unintended weight loss, progressive dysphagia, persistent vomiting, abdominal mass, and fever
• Diagnosed with accompanying GI or other disease (e.g., GI tumors, peptic ulcer, and hiatal hernia)
• Conditions with elevated health risk if having increased gastric motility (e.g., GI hemorrhage, mechanical obstruction or perforation)
• Hepatic dysfunction and renal insufficiency
• Concomitant use with oral ketoconazole, erythromycin, or other potent inhibitors of CYP3A4 enzymes that may prolong the QTc interval (refer to Chinese OTC label. e.g., fluconazole, voriconazole, clarithromycin, amiodarone, telithromycin, itraconazole, posaconazole, ritonavir, saquinavir, and telaprevir)
• Known allergies to Motilium (domperidone) or any other ingredient of Motilium
• Pregnant, breast feeding female or planning to become pregnant (either potential participant or potential participant's partner)
• Individuals who are currently taking Motilium
• Individuals who did not get relieved from dyspepsia-related symptoms after taking Motilium
• Individuals participating in any other clinical trials during this study

Study participant recruitment will occur at retail pharmacies in different provinces across China. Consumers assessed in this study are adult participants who purchase OTC Motilium at pharmacies to treat dyspepsia-related symptoms in China. Consumers who fulfill the pre-defined inclusion and exclusion criterion and sign the informed consent form are study participants. The decision of individuals to participate in this study must not, in any way, impact upon the standard of care that they are receiving or any benefits to which they are otherwise entitled. The treatment decision must have been taken prior to and independently of the patient's inclusion in the study.